

# Carcinoma of the Oesophagus Histopathology Reporting Guide



Family/Last name

Date of birth

Given name(s)

Patient identifiers

Date of request

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

[SCOPE OF THIS DATASET](#)

indicates multi-select values     indicates single select values

## CLINICAL INFORMATION (select all that apply)

- Information not provided
- Relevant biopsy results, *specify*
- Previous diagnosis and treatment for oesophageal cancer, *specify*
- Endoscopic location of the tumour, *specify levels (upper/middle/lower)*
- Clinical staging, *specify level of involvement, distant metastases*
- History of gastroesophageal reflux and/or Barrett oesophagus
- Other (e.g., previous history of cancer), *specify*

## NEOADJUVANT THERAPY

- Not administered
- Information not provided
- Administered, *describe*

## OPERATIVE PROCEDURE (select all that apply)

- Not specified
- Pharyngo-laryngo-oesophagectomy
- Oesophagectomy/oesophagogastrrectomy
- Lymph nodes, *describe site(s) from which taken if sent separately by surgeon*
- Other, *specify*

## SPECIMEN DIMENSIONS

Length of tubular oesophagus  
(Record per specimen)

Specimen 1	Specimen 2	Specimen 3
<input type="text" value="mm"/>	<input type="text" value="mm"/>	<input type="text" value="mm"/>

Length of stomach, from oesophagogastric junction to distal gastric resection margin (if present)

## MACROSCOPIC APPEARANCE

- No macroscopically detectable lesion
- Scar/thickening
- Protruding/fungating/polypoid
- Ulcerative tumour
- Diffuse infiltrative

## TUMOUR FOCALITY<sup>a</sup>

- Unifocal
- Multifocal, *specify number of tumours in specimen*
- Cannot be assessed, *specify*

<sup>a</sup> If multiple primary tumours are present, separate datasets should be used to record this and all following elements for each primary tumour.

## TUMOUR SITE (select all that apply)

- Not specified
  - Cervical (proximal) oesophagus
  - Upper thoracic oesophagus
  - Middle thoracic oesophagus
  - Lower thoracic (distal) oesophagus
  - Oesophagogastric junction (OGJ) with tumour epicentre ≤20 mm into the proximal stomach
  - Other, *specify*
- Distance from epicentre/midpoint of tumour to OGJ

**TUMOUR DIMENSIONS** 

Maximum tumour dimension

Additional dimensions

 x 

- No macroscopically visible tumour
- Cannot be assessed, *specify*

**BARRETT MUCOSA** 

- Not identified
- Present

**MACROSCOPIC DISTANCE OF TUMOUR TO THE MARGIN** 

- Cannot be assessed
- Involved
- Not involved

Distance of tumour from closest margin Specify closest margin **HISTOLOGICAL TUMOUR TYPE** *(Value list based on the World Health Organization Classification of Tumours of the Digestive System (2019))*

- Cannot be assessed
- Squamous cell carcinoma
- Conventional
- Verrucous
- Spindle cell carcinoma
- Basaloid squamous cell carcinoma
- Adenocarcinoma
- Tubular
- Papillary
- Mucinous
- Poorly cohesive carcinoma
- Signet ring
- Non-signet ring
- Mucoepidermoid
- Adenosquamous carcinoma
- Adenoid cystic carcinoma
- Undifferentiated carcinoma
- Neuroendocrine neoplasms<sup>b</sup>
- Neuroendocrine carcinoma
- Small cell
- Large cell
- Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)
- Other, *specify*

<sup>b</sup> Neuroendocrine tumour is not covered in this dataset.**DYSPLASIA** 

- Not applicable
- Cannot be assessed
- Not identified
- Present

**Type**

- Squamous
- Columnar/Barrett

**Grade**

- Low grade
- High grade
- Cannot be assessed, *specify*

**HISTOLOGICAL TUMOUR GRADE** *(Applicable to squamous cell carcinoma and adenocarcinoma)*

- GX: Cannot be assessed
- Grade 1 (G1): Well differentiated
- Grade 2 (G2): Moderately differentiated
- Grade 3 (G3): Poorly differentiated

**EXTENT OF INVASION** 

- Cannot be assessed
- No evidence of primary tumour
- Dysplasia
- Invasion into the lamina propria
- Invasion into the muscularis mucosae
- Invasion into the submucosa
- Invasion into the muscularis propria
- Invasion into the adventitia
- Invasion into the visceral peritoneum, azygous vein, diaphragm, pleura, pericardium
- Invasion into adjacent structures/organs, *specify*

**LYMPHOVASCULAR INVASION** 

- Not identified
- Present (select all that apply)
- Small vessel (lymphatic, capillary or venular), *specify the type of vessel, if possible*

- Large vessel (venous)

**PERINEURAL INVASION** 

- Not identified
- Present

**RESPONSE TO NEOADJUVANT THERAPY** 

Cannot be assessed, *specify*

**Mandard system**

- Absence of residual cancer with fibrosis extending throughout (complete response)
- Rare residual cancer cells scattered through the fibrosis
- An increase in the number of residual cancer cells, but fibrosis still predominates
- Residual cancer outgrowing fibrosis
- Absence of regressive changes

**OR**

**Becker system**

- No carcinoma present (complete response)
- <10% carcinoma present
- 10-50% carcinoma present
- >50% carcinoma present

**OR**

**Modified Ryan system**

- No neoadjuvant treatment
- Complete response - no viable cancer cells (score 0)
- Near complete response - single cells or rare small groups of cancer cells (score 1)
- Partial response - residual cancer with evident tumour regression, but more than single cells or rare small groups of cancer cells (score 2)
- Poor or no response - extensive residual cancer with no evident tumour regression (score 3)

**MARGIN STATUS** 

**Invasive carcinoma**

- Cannot be assessed
- Not involved
- Distance of tumour from closest margin  mm

Specify closest margin, if possible

Involved (select all that apply)

- Distal
- Proximal
- Circumferential/Radial

**Dysplasia**

- Cannot be assessed
- Not involved
- Distance of dysplasia from closest margin  mm

Specify closest margin, if possible

Involved

- Squamous
  - High grade
  - Low grade
- Columnar/Barrett
  - High grade
  - Low grade

Specify margin (select all that apply)

- Distal
- Proximal

**LYMPH NODE STATUS** 

- Cannot be assessed
- No nodes submitted or found

Number of lymph nodes examined

- Not involved
- Involved

Number of involved lymph nodes

**Extranodal extension**

- Not identified
- Present
- Cannot be determined

**COEXISTENT PATHOLOGY** (select all that apply) 

- None identified
- Synchronous carcinoma(s), *specify*

Other, *specify*

**ANCILLARY STUDIES** 

**For neuroendocrine neoplasms only**

- Not applicable
- Neuroendocrine markers (chromogranin A, synaptophysin, other), *specify test(s) performed and result(s) if available*

AND  
 Ki-67 proliferation index  %

**Other oesophageal carcinomas**

- Not performed
- Performed (select all that apply)
- HER2 testing performed, *record results*

PD-L1, *specify*

Microsatellite instability, *specify*

Other, *specify test(s) and result(s)*

**HISTOLOGICALLY CONFIRMED DISTANT METASTASES** 

- Not identified
- Present, *specify site(s)*

--

**PATHOLOGICAL STAGING (UICC TNM 8<sup>th</sup> edition)<sup>c,d</sup>** **TNM Descriptors** (only if applicable)

- No adjuvant therapy
- y - post-therapy

**Primary tumour (pT)**

- TX Primary tumour cannot be assessed
- T0 No evidence of primary tumour
- Tis Carcinoma in situ/high grade dysplasia
- T1 Tumour invades lamina propria, muscularis mucosae, or submucosae
- T1a Tumour invades lamina propria or muscularis mucosae
- T1b Tumour invades submucosa
- T2 Tumour invades muscularis propria
- T3 Tumour invades adventitia
- T4 Tumour invades adjacent structures
- T4a Tumour invades pleura, pericardium, azygos vein, diaphragm, or peritoneum
- T4b Tumour invades other adjacent structures such as aorta, vertebral body, or trachea

**Regional lymph nodes (pN)**

- NX Regional lymph nodes cannot be assessed
- N0 No regional lymph node metastasis
- N1 Metastasis in 1 to 2 regional lymph nodes
- N2 Metastasis in 3 to 6 regional lymph nodes
- N3 Metastasis in 7 or more regional lymph nodes

<sup>c</sup> Reproduced with permission. Source: *UICC TNM Classification of Malignant Tumours, 8<sup>th</sup> Edition*, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 25<sup>th</sup> January 2022).

<sup>d</sup> Refer to Note for AJCC 8<sup>th</sup> Edition staging of oesophageal adenocarcinomas and squamous cell carcinomas with or without neoadjuvant therapy.